Introduction
CED, Prognosis of stage, toxicity, triple-negative breast cancer, tumors
TRIPLE-NEGATIVE BREAST CANCER, TUMORS, BREAST CANCER
Prognosis of stage III triple-negative breast cancer patients is still poor [Objectively, HDCT has only shown limited clinical benefit in high-risk breast cancer, at the expense of considerable toxicity during the first year after diagnosis, and long-term toxicity comparable to conventional chemotherapy [Strikingly, in an unplanned subgroup analysis of patients with homologous recombination deficient (HRD) tumors, Therefore, the ongoing SUBITO trial (NCT02810743) randomizes patients with stage III, HER2 negative, HRD tumors to the current Dutch standard of care plus a Poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib) or to HDCT. This trial investigates multiple outcomes, such as prognosis, quality of life, effect of chemotherapy on cognition, and cost-effectiveness. The SUBITO trial is part of a Coverage with Evidence Development (CED) trajectory due to the promising results in the retrospective analyses. This means that HDCT is conditionally reimbursed, targeted data is collected, and a timely reimbursement decision will be made after the study [Generally, Health Technology Assessment (HTA) is used to evaluate medical, economic, organizational, social and ethical aspects to help provide evidence for decision-making and develop guidance on reimbursement [To increase the chance of a successful introduction of HDCT into daily clinical practice, good preparation and planning of implementation activities are necessary [